Prostatype Genomics AB Logo

Prostatype Genomics AB

Provides a genetic test to assess prostate cancer aggressiveness and guide treatment choices.

PROGEN | ST

Overview

Corporate Details

ISIN(s):
SE0022574554 (+2 more)
LEI:
549300JO6MPCGPVHVU91
Country:
Sweden
Address:
Gustav III:s Boulevard 34, 169 73 Solna
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. The test is designed to provide a comprehensive assessment of the aggressiveness of diagnosed prostate cancer, particularly for patients with localized disease. It serves as a decision-making tool for clinicians and patients to help determine appropriate treatment strategies. The Prostatype® system uses existing biopsy tissue to analyze the expression of three key genes. This genetic data is combined with standard clinical parameters (PSA, Gleason Score, Tumor Stage) to calculate a proprietary P-score, which quantifies the risk of cancer mortality. By offering a more precise prognosis, the test aims to minimize both over- and under-treatment, thereby improving patient quality of life and saving healthcare resources.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prostatype Genomics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prostatype Genomics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prostatype Genomics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
WDB coco CO.,LTD. Logo
CRO for pharma & med devices specializing in safety info, PMS & full lifecycle support.
Japan
7079
Whitehawk Therapeutics, Inc. Logo
Develops advanced antibody-drug conjugates (ADCs) for difficult-to-treat cancers.
United States of America
WHWK
WOOJUNG BIO, Inc. Logo
Integrated R&D platform offering CRO services, lab construction, and biotech incubation.
South Korea
215380
XEROS TECHNOLOGY GROUP PLC Logo
Develops tech for laundry/apparel to cut water use and capture microplastic pollution.
United Kingdom
XSG
Xilio Therapeutics, Inc. Logo
Engineering tumor-activated biologics for cancer to maximize efficacy and minimize toxicity.
United States of America
XLO
Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden
XINT
Xlife Sciences AG Logo
A life sciences incubator commercializing early-stage academic research for healthcare markets.
Switzerland
XLS
Y-Biologics, Inc Logo
Develops novel antibody cancer therapies using proprietary T-cell engager & antibody library tech.
South Korea
338840
YD Bio Ltd Logo
Developing blood-based cancer detection and regenerative therapies for biopharma partners.
United States of America
YDES

Talk to a Data Expert

Have a question? We'll get back to you promptly.